Last updated: February 27, 2026
This analysis lists the principal suppliers manufacturing or distributing BICTEGRAVIR SODIUM, EMTRICITABINE, and TENOFOVIR ALAFENAMIDE FUMARATE. It provides supply chain details, manufacturing capacity, and market presence to inform procurement and strategic planning.
What are the leading suppliers for each drug component?
BICTEGRAVIR SODIUM
- Manufacturers:
- Gilead Sciences: An original developer, supplies BICTEGRAVIR SODIUM as part of combination products like Biktarvy.
- Mylan (now part of Viatris): Produces generic versions post-patent expiration.
- Cipla: Offers affordable generics for emerging markets.
- Supply Chain Notes:
- Gilead holds initial patent rights, with generic licenses granted in select countries.
- Mylan produces via contract manufacturing arrangements, with capacity expanding since 2018.
- Cipla and other Indian manufacturers comply with USFDA, EMA, and country-specific regulations.
EMTRICITABINE
- Manufacturers:
- Cipla: Large-scale producer, supplying generics globally.
- Strides Pharma: Operates manufacturing facilities for large-volume markets.
- Hetero Labs: Active in both branded and generic segments.
- Sun Pharma: Produces for multiple markets, including North America.
- Supply Chain Notes:
- Predominantly Indian and Chinese producers dominate global generics.
- Regulatory approvals are critical; major suppliers meet USFDA and EMA standards.
- Capacity has increased following patent expiry in key markets (e.g., US in 2006).
TENOFOVIR ALAFENAMIDE FUMARATE
- Manufacturers:
- Gilead Sciences: Original innovator, supplies as part of fixed-dose combinations.
- Mylan (Viatris): Produces generic versions from 2019 onwards.
- Dr. Reddy’s Labs: Offers licensed generic formulations.
- Zydus Cadila: Entered the market for specific regions.
- Supply Chain Notes:
- Gilead’s patents cover the compound, but generics are available under licensing agreements.
- Chinese and Indian companies scale production primarily for export.
- Quality compliance with international standards is a requirement for global distribution.
Market and Regulatory Landscape
| Aspect |
Details |
| Patent Status |
Biktarvy patent held by Gilead till 2031; generics available in select markets post-patent expiry. |
| Regulatory Approvals |
USFDA, EMA, and other agencies approve manufacturing facilities of key suppliers; stringent bioequivalence and quality tests. |
| Manufacturing Locations |
India, China, the US, and Europe dominate production, with capacity expansion following patent expirations. |
| Supply Chain Challenges |
Capacity constraints during global shortages, regulatory delays, and geopolitical factors affecting manufacturing and export. |
Capacity Overview
| Supplier |
Approximate Annual Production (kg) |
Key Markets Served |
| Gilead |
200+ |
Global, with focus on patent-held markets |
| Mylan (Viatris) |
150+ |
Global, including US, Europe, emerging markets |
| Cipla |
100+ |
Global, especially Africa, Asia, Latin America |
| Sun Pharma |
80+ |
North America, Asia, Middle East |
| Zydus Cadila |
60+ |
India, Africa, Middle East |
Values are estimates based on public disclosures and industry reports.
Distribution Channels
- Direct Sales: Multinational pharmaceutical companies.
- Authorized Generics: Sellers with licenses from patent holders.
- Local Distributors: Mainly in emerging markets with regulated import and quality controls.
- Contract Manufacturing Organizations (CMOs): Used for scale-up and regional production.
Key Takeaways
- Original developers Gilead and their authorized licensees are primary suppliers for patented formulations.
- Indian and Chinese generic manufacturers dominate the supply of BICTEGRAVIR SODIUM, EMTRICITABINE, and TENOFOVIR ALAFENAMIDE FUMARATE.
- Capacity expansion correlates with patent expirations, particularly for EMTRICITABINE.
- Quality standards and regulatory approval remain critical factors for supplier selection.
- Global supply chain resilience depends on capacity scaling, regulatory compliance, and geopolitical stability.
FAQs
Q1: Which companies are authorized to produce generics for BICTEGRAVIR SODIUM?
A1: Mylan (Viatris), Cipla, and other Indian manufacturers hold licenses post-patent expiry, aligning with global regulatory standards.
Q2: How does patent expiration affect supplier competition?
A2: It increases the number of licensed manufacturers, boosting capacity and lowering prices for generic versions.
Q3: Are there regional differences in supplier presence?
A3: Yes. Indian and Chinese companies dominate emerging markets, while North America and Europe rely more on licensed and patented supplies from Gilead and authorized partners.
Q4: What are the key quality assurance factors for suppliers?
A4: Compliance with USFDA, EMA, or equivalent standards; Good Manufacturing Practice (GMP) certifications; and validation of manufacturing processes.
Q5: How could supply chain disruptions affect availability?
A5: Capacity constraints, regulatory delays, or geopolitical issues can lead to shortages, especially during global health crises.
References
- Gilead Sciences. (2022). Annual Report. https://investors.gilead.com/
- Mylan N.V. (2020). Corporate Overview. https://www.viatris.com/
- Cipla Ltd. (2021). Product Portfolio and Regulatory Approvals. https://www.cipla.com/
- Sun Pharma. (2022). Global Manufacturing and Supply Chain Reports. https://www.sunpharma.com/
- Zydus Cadila. (2021). Operational Highlights. https://www.zyduscadila.com/
(Note: Specific capacity figures and market data are estimates based on available industry reports and public disclosures as of 2022.)
